All In Biotech

Drug Trial Radar · NCT07546500

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Apr 17, 2026

Primary completion

May 31, 2028

Study completion Apr 30, 2030

Sponsor

Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.

Conditions

  • Ovarian Cancer

Interventions

  • Investigator's choice of ChemotherapyDrug

    The investigator will select the chemotherapy in accordance with the protocol defined requirements. The possible choices as defined by the protocol: * Paclitaxel * Gemcitabine * Pegylated liposomal doxorubicin (PLD) * Topotecan The selected chemotherapy will be administered intravenously

  • AzenosertibDrug

    Azenosertib 400 mg will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) per RECIST v1.1 as assessed by InvestigatorTime frame: Up to approximately 24 months from the enrollment of the last subject

Locations

129 sites in 22 countries. Site status is shown where the registry gives one.

  • Site 0107

    Phoenix, Arizona · Not yet recruiting

  • Site 0110

    Antioch, California · Not yet recruiting

  • Site 0104

    Beverly Hills, California · Recruiting

  • Site 0122

    Fountain Valley, California · Recruiting

  • Site 0115

    San Francisco, California · Not yet recruiting

  • Site 0101

    Torrance, California · Recruiting

  • Site 0116

    Orlando, Florida · Recruiting

  • Site 0123

    Baltimore, Maryland · Recruiting

  • Site 0111

    Camden, New Jersey · Not yet recruiting

  • Site 0108

    Columbus, Ohio · Not yet recruiting

  • Site 0105

    Portland, Oregon · Not yet recruiting

  • Site 0109

    Philadelphia, Pennsylvania · Recruiting

  • Site 0113

    Philadelphia, Pennsylvania · Not yet recruiting

  • Site 0114

    Willow Grove, Pennsylvania · Not yet recruiting

  • Site 0112

    Sioux Falls, South Dakota · Not yet recruiting

  • Site 0117

    Fort Worth, Texas · Recruiting

  • Site 2105

    Buenos Aires, Argentina · Not yet recruiting

  • Site 2101

    Córdoba, Argentina · Not yet recruiting

  • Site 2102

    Córdoba, Argentina · Not yet recruiting

  • Site 2104

    Rosario, Argentina · Not yet recruiting

  • Site 2103

    San Miguel de Tucumán, Argentina · Not yet recruiting

  • Site 1101

    Randwick, New South Wales, Australia · Recruiting

  • Site 1105

    Westmead, New South Wales, Australia · Not yet recruiting

  • Site 1108

    Wollongong, New South Wales, Australia · Not yet recruiting

  • Site 1107

    South Brisbane, Queensland, Australia · Not yet recruiting

  • Site 1102

    Adelaide, South Australia, Australia · Recruiting

  • Site 1103

    Nedlands, Western Australia, Australia · Not yet recruiting

  • Site 1104

    Subiaco, Western Australia, Australia · Not yet recruiting

  • Site 3002

    Brussels, Belgium · Recruiting

  • Site 3003

    Edegem, Belgium · Not yet recruiting

  • Site 3001

    Leuven, Belgium · Not yet recruiting

  • Site 2209

    Belo Horizonte, Brazil · Not yet recruiting

  • Site 2208

    Curitiba, Brazil · Not yet recruiting

  • Site 2207

    Goiânia, Brazil · Not yet recruiting

  • Site 2201

    Porto Alegre, Brazil · Not yet recruiting

  • Site 2203

    Porto Alegre, Brazil · Not yet recruiting

  • Site 2205

    Rio de Janeiro, Brazil · Not yet recruiting

  • Site 2206

    Rio de Janeiro, Brazil · Not yet recruiting

  • Site 2202

    São José do Rio Preto, Brazil · Not yet recruiting

  • Site 2204

    São Paulo, Brazil · Not yet recruiting

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.